Acadia Pharmaceuticals

ACAD

Market cap $3.48B

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's website, acadia.com under the investors section and will be archived there until February 5, 2026. The confe.

NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

ACAD's thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD's Q2 2025 revenues remain solid with Nuplazid and Daybue. Also, a near-term catalyst could be the EMA's decision for Daybue by Q1 2026. They also recently secured patent wins that should protect Nuplazid until 2030 and 2038, supporting durable cash flows.

NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company's robust pipeline including preclinical efficacy, safety and mechanism of action findings on Acadia's investigational drug ACP-711, under deve.

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Acadia Pharmaceuticals Inc. ACAD released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).

Shares of Acadia Pharmaceuticals toppled Wednesday after the biotech company's experimental treatment for a rare, genetic disorder failed.